Nicole Brown
Psychiatric/Mental Health · Oklahoma City, OKNPI 1518531227
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Johnson & Johnson at 35.1% of the total. 2025 is the largest year on record at $2,497, more than ten times the $115 reported in 2021. Among psychiatric/mental health clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $43.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Alkermes, Inc.$841
- Teva Pharmaceuticals USA, Inc.$631
- Otsuka America Pharmaceutical, Inc.$622
- Neurocrine Biosciences, Inc.$607
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$504
- plus $2K from 11 others
What the payments were for
- Food & beverage$7,596100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 62 | $2,666 |
| Alkermes, Inc. | 19 | $841 |
| Teva Pharmaceuticals USA, Inc. | 16 | $631 |
| Otsuka America Pharmaceutical, Inc. | 11 | $622 |
| Neurocrine Biosciences, Inc. | 13 | $607 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $504 |
| Axsome Therapeutics, Inc. | 5 | $387 |
| AbbVie | 17 | $360 |
| E.r. Squibb & Sons, L.L.C. | 5 | $256 |
| Lundbeck LLC | 7 | $158 |
| AstraZeneca | 2 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| Sage Therapeutics, LLC | 2 | $115 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $101 |
| Indivior Inc. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$1,111
- LYBALVI$907
- SPRAVATO$380
- CAPLYTA$343
- INGREZZA$248
- REXULTI$247
- ABILIFY MAINTENA$241
- COBENFY$238
- VIVITROL$233
- Auvelity$233
- INVEGA TRINZA$232
- VRAYLAR$125
- AUSTEDO$122
- ABILIFY ASIMTUFII$117
- Austedo XR$116
- SUNOSI$116
- AIRSUPRA$115
- Mavyret$105
How this compares
$7,602 in reported general payments places this provider in the 90th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 27 | $76,450 |
| Abilify MaintenaAripiprazole | 13 | $35,583 |
| VraylarCariprazine Hcl | 11 | $17,057 |
| Lurasidone Hcl | 16 | $1,926 |
| Aripiprazole | 57 | $1,447 |
| Quetiapine Fumarate | 59 | $1,265 |
| Hydroxyzine Pamoate | 58 | $1,027 |
| Hydroxyzine Hcl | 16 | $1,023 |
| Buspirone Hcl | 50 | $965 |
| Ziprasidone Hcl | 18 | $945 |
| Doxepin Hcl | 21 | $898 |
| Trazodone Hcl | 69 | $695 |
| Olanzapine | 38 | $639 |
| Benztropine Mesylate | 38 | $437 |
| Divalproex Sodium | 25 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $2,666 | $76,45027 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $622 | $35,58313 claims |
| AbbVieVraylar | $360 | $17,05711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Oklahoma City
- Sylvie MawohOklahoma City$14K
- Imelda GarnerOklahoma City$9K
- Kathryn SheltonOklahoma City$8K
- Ragina HolimanOklahoma City$7K
- Tierra PageOklahoma City$7K
- Kelsey WilsonOklahoma City$6K
- Jamie HolzOklahoma City$6K
- Robin Potter-KimballOklahoma City$6K
- Sue RollinsOklahoma City$6K
- Elizabeth MuburiOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.